Black Rock Inc. Moleculin Biotech, Inc. Transaction History

Black Rock Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.41 - $0.86 $3,023 - $6,341	-7,374 Reduced 3.76%	188,924 $162,000
Q3 2023 Nov 13, 2023	BUY	$0.38 - $0.72 $38 - $73	102 Added 0.05%	196,298 $84,000
Q2 2023 Aug 11, 2023	SELL	$0.54 - $0.95 $33,747 - $59,371	-62,496 Reduced 24.16%	196,196 $113,000
Q1 2023 May 12, 2023	BUY	$0.9 - $1.34 $1,667 - $2,483	1,853 Added 0.72%	258,692 $248,000
Q4 2022 Feb 13, 2023	SELL	$0.85 - $16.65 $5,141 - $100,715	-6,049 Reduced 2.3%	256,839 $272,000
Q3 2022 Nov 14, 2022	SELL	$1.15 - $17.4 $2,480 - $37,531	-2,157 Reduced 0.81%	262,888 $278,000
Q2 2022 Aug 12, 2022	SELL	$1.19 - $2.0 $321 - $540	-270 Reduced 0.1%	265,045 $384,000
Q1 2022 May 12, 2022	SELL	$1.23 - $1.9 $11,146 - $17,217	-9,062 Reduced 3.3%	265,315 $472,000
Q4 2021 Feb 10, 2022	BUY	$1.64 - $2.83 $6,519 - $11,249	3,975 Added 1.47%	274,377 $510,000
Q3 2021 Nov 09, 2021	SELL	$2.7 - $3.59 $18,478 - $24,569	-6,844 Reduced 2.47%	270,402 $812,000
Q2 2021 Aug 11, 2021	BUY	$3.21 - $4.06 $889,959 - $1.13 Million	277,246 New	277,246 $1.02 Million

3.35K

Ticker MBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,606,700
Market Cap $72.7M
Description
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.